Saxenda Week by Week: What to Expect in Your First Month on Liraglutide 3 mg

What the first month is designed to do

Saxenda is liraglutide, a GLP-1 receptor agonist injected under the skin once a day, used with a reduced-calorie diet and more physical activity for chronic weight management [1]. The label moves the dose up every week (0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, then 3 mg from week 5) and says the escalation schedule is meant to reduce the risk of gastrointestinal adverse reactions [1]. For adults, 3 mg daily is the recommended dose, and the lower doses are for titration only [1].

Two label rules matter during the ramp:

• If an increased dose is not tolerated, the label says to consider delaying escalation by approximately one additional week [1].
• For adults, if the 3 mg dose cannot be tolerated, the label discontinues Saxenda rather than keeping the patient on a lower long-term dose [1].

Saxenda is injected once daily at any time of day, with or without meals, into the abdomen, thigh or upper arm. Changing the injection site or timing needs no dose adjustment [1].

Week 1: 0.6 mg daily

Treatment starts at 0.6 mg daily for one week [1]. Liraglutide reaches peak plasma levels about 11 hours after an injection and has a half-life of about 13 hours, hence the once-daily dosing [1].

Across the adult trials, injection-site reactions were reported by 13.9% of Saxenda-treated adults versus 10.5% on placebo [1].

Week 2: 1.2 mg daily

At week 2 the dose rises to 1.2 mg daily as the first step of the weekly escalation [1]. Across the adult trials, 2.9% of Saxenda-treated adults stopped treatment because of nausea versus 0.2% on placebo [1].

Week 3: 1.8 mg daily

The label asks for heart rate to be monitored at regular intervals during Saxenda treatment [1]. Across the adult trials the mean resting heart rate rose 2 to 3 beats per minute compared with placebo, and in a clinical pharmacology trial with 24-hour monitoring the difference was 4 to 9 beats per minute [1]. More Saxenda-treated patients had a rise of more than 10 beats per minute at two consecutive visits (34% versus 19%), and 6% had at least one resting rate above 100 beats per minute versus 4% on placebo [1].

Week 4: 2.4 mg daily

Week 4 is the last step before the recommended dose. Gallbladder disease is one of the label's warnings: cholelithiasis was reported in 2.2% of Saxenda-treated adults versus 0.8% on placebo, and cholecystitis in 0.8% versus 0.4% [1]. The label notes that the excess was present even after accounting for the degree of weight lost [1].

Week 5 onward: 3 mg and the 16-week checkpoint

From week 5 the dose is 3 mg daily [1]. For adults, the label's first formal check on whether the drug is working comes at 16 weeks, when it directs that treatment be stopped if the patient has not lost at least 4% of baseline body weight [1]. In a pooled analysis of the two SCALE trials, losing at least 4% by week 16 best predicted reaching 5% loss by week 56, and 77.3% of liraglutide-treated participants without type 2 diabetes met that criterion [2].

Side effects reported in the adult trials

The adult safety data come from five placebo-controlled trials with 3,384 people on Saxenda and 1,941 on placebo, treated for up to 56 weeks [1]. The common reactions, Saxenda versus placebo:

• Nausea 39.3% vs 13.8% [1]
• Diarrhea 20.9% vs 9.9% [1]
• Constipation 19.4% vs 8.5% [1]
• Vomiting 15.7% vs 3.9% [1]
• Injection-site reactions 13.9% vs 10.5% [1]
• Headache 13.6% vs 12.6% [1]
• Dyspepsia 9.6% vs 2.7% [1]
• Fatigue 7.5% vs 4.6% [1]
• Dizziness 6.9% vs 5.0% [1]

About 68% of Saxenda-treated adults reported a gastrointestinal disorder versus 39% on placebo [1]. Overall, 9.8% of adults stopped Saxenda because of adverse reactions, versus 4.3% on placebo [1].

Weight change over 56 weeks

In a 56-week trial of 3,731 adults without type 2 diabetes, 2,487 received liraglutide 3 mg daily and 1,244 received placebo [3]. Mean weight loss was 8.4 kg versus 2.8 kg; 63.2% versus 27.1% lost at least 5% of body weight and 33.1% versus 10.6% lost more than 10% [3]. The label's own analysis of the same trial, using a different method for missing data, gives a body-weight change of -7.4% versus -3.0% and a 5% responder rate of 62.3% versus 34.4% [1].

In a 56-week trial of 846 adults with type 2 diabetes, participants receiving liraglutide 3 mg lost 6.0% of body weight versus 2.0% on placebo [4].

Missed or late doses

The label says that if a dose is missed, the once-daily regimen resumes with the next scheduled dose, and no extra dose is taken to make up for it [1]. If more than 3 days have passed since the last Saxenda dose, the label restarts treatment at 0.6 mg and repeats the escalation schedule, to reduce gastrointestinal adverse reactions from reinitiation [1].

Adolescents aged 12 and older

The label covers adolescents aged 12 and older with body weight above 60 kg and obesity [1]. Pediatric dose escalation may take up to 8 weeks, and a pediatric patient who does not tolerate 3 mg daily may have the dose reduced to 2.4 mg daily [1]. In the 56-week pediatric trial (125 on liraglutide, 126 on placebo), nausea occurred in 42.4% versus 14.3% and vomiting in 34.4% versus 4%, and 10.4% versus 0% stopped treatment for adverse reactions [1]. The trial's primary measure, the BMI standard-deviation score, improved by an estimated difference of -0.22 in favour of liraglutide [5].

Serious risks the label lists alongside the common ones

• Acute pancreatitis. The label says to discontinue Saxenda if pancreatitis is suspected [1].
• Acute gallbladder disease. If gallstones or cholecystitis are suspected, the label says gallbladder studies are indicated [1].
• Acute kidney injury from volume depletion. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion [1].
• Hypersensitivity. Serious reactions including anaphylaxis and angioedema have been reported; the label says to discontinue Saxenda and other suspect medicines [1].
• Pulmonary aspiration during general anesthesia or deep sedation. The label instructs patients to tell healthcare providers about any planned surgery or procedure [1].
• Thyroid C-cell tumors. The boxed warning applies; Saxenda is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1].
• Mood. The current Saxenda label no longer includes a suicidal behavior and ideation warning [1]. FDA requested its removal after a review found no increased risk with GLP-1 receptor agonists [6].